Price movement over the last 24 hours
Abbott Laboratories vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.35. The key difference: Abbott Laboratories pays a 2.63% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals.
| ABT | EMLC | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Fixed Income |
52-Week High | $136.62 | $26.59 |
52-Week Low | $82.57 | $24.83 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EMLC trades at $25.59 with a modest 0.51% daily gain, showing bullish technical momentum with strong moving average support. The ETF maintains a consistent dividend distribution pattern with recent $0.14 payouts, while technical indicators show mixed signals with RSI in neutral territory. Emerging market debt remains in focus as investors seek yield above Treasury bonds amid shifting global monetary policy.
The outlook for EMLC hinges on Federal Reserve policy and emerging market stability. The 6.09% yield provides income appeal, but currency risk and short interest growth present challenges. Institutional demand for EM debt is rising, though sustainability concerns warrant monitoring given the 73% short interest surge reported in April 2026.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →